FDA OKs Varisolve varicose vein therapy trial:
This article was originally published in Clinica
BTG's subsidiary Provensis has gained approval from the US FDA to begin a pilot clinical study of its noninvasive procedure for treating varicose veins. The technique, called Varisolve, involves injecting a microfoam version of a standard sclerosing liquid into the vein under ultrasound guidance. Efficacy data from an ongoing trial in Europe are expected to become available by the end of the year, at which time BTG plans to begin discussions with potential sales and marketing partners. London, UK-based BTG forecasts 2006 and 2005 launch dates for Varisolve in the US and in Europe, respectively.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.